What is he best known for?
The fields of study he is best known for:
Alexey V. Pshezhetsky focuses on Biochemistry, NEU1, Sialidase, Cathepsin A and Sialidosis.
His work on Cell biology expands to the thematically related Biochemistry.
Alexey V. Pshezhetsky has researched NEU1 in several fields, including Molecular biology and Endosome.
His work in Cathepsin A addresses subjects such as Lysosome, which are connected to disciplines such as Sulfatase.
His Sialidosis study combines topics in areas such as NEU2 and Missense mutation.
His research in the fields of Linkage disequilibrium overlaps with other disciplines such as CDKAL1, Epigenetics of diabetes Type 2, TCF7L2 and Population stratification.
His most cited work include:
- A genome-wide association study identifies novel risk loci for type 2 diabetes (2537 citations)
- De Novo Mutations in Moderate or Severe Intellectual Disability (242 citations)
- Cloning, expression and chromosomal mapping of human lysosomal sialidase and characterization of mutations in sialidosis. (166 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Biochemistry, Sialidase, Molecular biology, Cell biology and Neuraminidase.
His Sialidase research includes elements of Sialic acid and N-Acetylneuraminic acid.
His Molecular biology research is multidisciplinary, incorporating elements of Nonsense mutation, Missense mutation, Gene, Cellular differentiation and Vacuolization.
His biological study spans a wide range of topics, including Caspase 3, Apoptosis, Cell and Glycolipid.
His research integrates issues of Endocrinology, Internal medicine, Glycoconjugate and Glycan in his study of Neuraminidase.
His NEU1 study incorporates themes from NEU2 and Glycoprotein.
He most often published in these fields:
- Biochemistry (51.95%)
- Sialidase (31.17%)
- Molecular biology (24.03%)
What were the highlights of his more recent work (between 2017-2021)?
- Neuroinflammation (15.58%)
- Neuraminidase (29.87%)
- Neurodegeneration (11.04%)
In recent papers he was focusing on the following fields of study:
Alexey V. Pshezhetsky mainly investigates Neuroinflammation, Neuraminidase, Neurodegeneration, Mucopolysaccharidosis and Sialic acid.
The concepts of his Neuraminidase study are interwoven with issues in Knockout mouse and Reproductive system.
The Neurodegeneration study combines topics in areas such as Mucopolysaccharidosis III, Neuroscience and Cell biology.
Alexey V. Pshezhetsky combines subjects such as Cell, Sialidase, Lysosome and Epithelium with his study of Cell biology.
His Sialic acid study improves the overall literature in Biochemistry.
His study on Structure–activity relationship, Glycan, NEU2 and Isozyme is often connected to Linker as part of broader study in Biochemistry.
Between 2017 and 2021, his most popular works were:
- A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency (46 citations)
- Anatomical changes and pathophysiology of the brain in mucopolysaccharidosis disorders (36 citations)
- Neuraminidase 1 activates insulin receptor and reverses insulin resistance in obese mice. (20 citations)
In his most recent research, the most cited papers focused on:
His scientific interests lie mostly in Neuraminidase, Catabolism, Cell biology, NEU1 and Mucopolysaccharidosis.
His Neuraminidase study is concerned with the field of Biochemistry as a whole.
His work on Glycan, NEU2, Enzyme and Potency as part of general Biochemistry research is often related to Linker, thus linking different fields of science.
The study incorporates disciplines such as Activator and Insulin resistance in addition to Catabolism.
His studies in Cell biology integrate themes in fields like Sialic acid, Lysosome, Sialidase, Neurodegeneration and Neuroinflammation.
Alexey V. Pshezhetsky has included themes like Insulin receptor, Receptor, Internal medicine, Insulin and Cathepsin A in his NEU1 study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
